Skip to main content
Download PDF

Headache medication and the COVID-19 pandemic

The Journal of Headache and Pain volume 21, Article number: 38 (2020) Cite this article

Abstract

The world is currently dominated by the Corona Virus Disease 2019 (COVID-19) pandemic. Besides the obvious concerns about limitation of virus spread and providing the best possible care to infected patients, a concomitant concern has now arisen in view of a putative link between the use of certain drugs, such as Renin-Angiotensin System (RAS) inhibitors and ibuprofen, and an increased risk for COVID-19 infection. We here discuss this concern in relation to headache treatment and conclude that, based on current evidence, there is no reason to abandon treatment of headache patients with RAS inhibitors or ibuprofen.

Background

The world is currently dominated by the pandemic spread of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which has already infected almost 2,000,000 people worldwide, leading to more than 120,000 deaths (for actual number, see https://who.sprinklr.com/). Whereas the priority of health authorities is to limit the spread of this virus and to provide the best possible care for patients [1], this pandemic also has consequences for the treatment of other diseases, such as headache. A statement from the European Headache Federation on how to currently treat headache patients (often from a distance) has recently been published (https://twitter.com/EMHAlliance/status/1243096347731001344). A concomitant concern has now arisen in view of a putative link between the use of certain drugs and an increased risk for COVID-19 infection [2]. This particularly applies to renin-angiotensin system (RAS) blockers and the non-steroid anti-inflammatory drug (NSAID) ibuprofen, and is based on the idea that these drugs upregulate the expression of Angiotensin-Converting Enzyme (ACE) 2, the receptor which facilitates SARS-CoV-2 entry [3]. Such entry depends on priming by the serine protease transmembrane protease, serine 2 (TMPRSS2) (Fig. 1).

Fig. 1
figure1

The carboxypeptidase angiotensin-converting enzyme 2 (ACE2) converts angiotensin (Ang) I into Ang-(1–9) and Ang II into Ang-(1–7) and (panel a), yet is not blocked by ACE inhibitors, which prevent the conversion of Ang I to Ang II. As depicted in (panel b), ACE2 also binds and internalizes SARS-Cov-2, after priming by the serine protease transmembrane protease, serine 2 (TMPRSS2). Shedding of membrane-bound ACE2 by a disintegrin and metalloprotease 17 (ADAM17) results in the occurrence of soluble (s) ACE2, which can no longer mediate SARS-Cov-2 entry, and which might even prevent such entry by keeping the virus in solution. Ang II, via its type 1 receptor (AT1R), upregulates ADAM17, and AT1R blockers (ARBs) would prevent this. Ibuprofen has been suggested to increase ACE2, possibly via inhibition of cyclooxygenases (COXs) and activation of Peroxisome Proliferator-Activated Receptor gamma (PPAR-γ). Redrawn after [4]

Full size image

RAS blockers are currently widely used as off-label drugs in the prophylactic treatment of migraine [5]. This mainly concerns the angiotensin-converting enzyme (ACE) inhibitors captopril and lisonopril and the angiotensin II type 1 receptor (AT1R) blocker (ARB) candesartan [6]. Ibuprofen is also widely used in the treatment of migraine [6], as well as in other types of headache or pain in general, because of its strong analgesic properties.

Apart from the usual considerations, such as drug-drug interactions or gastrointestinal safety the NSAIDs [7], in view of the suggested increased risk for COVID-19 infection by RAS inhibitors and ibuprofen, many clinicians now need to know what to advice their patients: continue treatment or not. The relation between RAS blockade and the COVID-19 pandemic in hypertensive patients has recently been discussed, and the advice was to continue RAS blocker treatment in such patients [4]. In this short communication, we discuss this concern in relation to headache treatment. We conclude that, based on current evidence, there is no reason to abandon treatment of headache patients with RAS inhibitors or ibuprofen.

Renin-angiotensin system (RAS) blockers and ACE2

The renin-angiotensin system is pivotal in the regulation of blood pressure. One of its main components is ACE, which converts angiotensin I (Ang I) into angiotensin II (Ang II). Ang II exerts its hypertensive effects via AT1R activation. Apart from ACE, there are multiple other enzymes that metabolize angiotensin (the so-called “angiotensinases”), and one of these is the carboxypeptidase angiotensin-converting enzyme 2 (ACE2). ACE2 converts the octapeptide Ang II (=Ang-(1–8)) into Ang-(1–7), and the decapeptide Ang I (=Ang-(1–10)) into Ang-(1–9) (Fig. 1). Yet, it additionally hydrolyzes multiple other peptides beyond the angiotensins. It is important to note that ACE2 does not convert Ang I into Ang II, and that its activity is not blocked by ACE inhibitors. This is not surprising, since ACE2 and ACE are different enzymes, and ACE inhibitors have been designed specifically for ACE only. ACE2 is a membrane-bound enzyme, with very low (soluble) levels in blood [8, 9]. The occurrence of sACE2 depends on cleavage of its membrane-anchor by A Disintegrin And Metalloprotease 17 (ADAM17) (Fig. 1). Interestingly, Ang II upregulates ADAM17. Yet, given that the vast majority of ACE2 is membrane-bound, fluctuations in the percentage of sACE by pathological conditions or drug use are unlikely to have major effects on the amount of membrane-bound ACE2. Obviously, SARS-CoV-2 entry relies exclusively on membrane-bound ACE2. sACE2 cannot mediate such entry, and, if anything, might even prevent it by keeping the virus in solution.

The concern related to the use of RAS blockers in COVID-19 patients is based on the idea that these drugs upregulate ACE2. Indeed, animal studies support such ACE2 upregulation after ARB treatment [10,11,12]. However, this generally required high doses, while effects differed per organ and per ARB. If true, this phenomenon should also be observed for ACE inhibitors. Yet, this has hardly been studied. Most importantly, we do not know whether the increase concerned membrane-bound ACE2 in pulmonary cells (relevant in SARS patients), nor whether a rise in membrane-bound ACE2, if occurring, truly facilitates virus entry. We do know that stopping RAS blocker treatment, particular in cardiovascular patients, has major serious consequences, including an increase in mortality.

Migraine patients using RAS blockers for the prevention of migraine often additionally suffer from hypertension. Normalizing increased blood pressure protects against cardiovascular disease, while migraine, especially in women, is associated with an increased cardiovascular risk [13]. Hence, suddenly aborting preventive treatment with RAS blockers is likely to impose an increased cardiovascular risk in migraine patients, similar to that in hypertensive patients.

Ibuprofen and ACE2

Like RAS inhibitors, ibuprofen has been suggested to increase ACE2 [14]. This conclusion is based on a study in diabetic rats exposed to one high dose of ibuprofen (40 mg/kg, corresponding with almost 3 g in a human being of 70 k). The increase in ACE2 was shown in the heart only, and no distinction was made between membrane-bound ACE2 and sACE2. Without providing evidence, the authors speculated that the ACE2 rise was due to inhibition of cyclo-oxygenase and/or activation of peroxisome proliferator-activated receptor γ [14]. Clearly, this is an exceptionally weak basis to draw a far-reaching conclusion on the use of ibuprofen in headache patients during the COVID-19 pandemic. Irrespective of this observation, we stress that paracetamol (acetaminophen) should be used as a first choice in headache treatment before starting with NSAIDs, given its better tolerability.

Conclusion

Summarizing, there is no convincing evidence that either RAS blockers or ibuprofen facilitate or worsen SARS-CoV-2 infection in any type of patient, including headache patients. In agreement with the advice of the main cardiovascular societies (American Heart Association, https://newsroom.heart.org/news/patients-taking-ace-i-and-arbs-who-contract-covid-19-should-continue-treatment-unless-otherwise-advised-by-their-physician, European Society of Hypertension, https://www.eshonline.org/spotlights/esh-stabtement-on-covid-19/, International Society of Hypertension, https://ish-world.com/news/a/A-statement-from-the-International-Society-of-Hypertension-on-COVID-19/), the World Health Organization (https://twitter.com/WHO/status/1240409217997189128) and European Medicines Agency (https://www.ema.europa.eu/en/news/ema-gives-advice-use-non-steroidal-anti-inflammatories-covid-19), we see no rationale to panic and to alter the prescription of these drugs that have an important role in the treatment of headache.

Availability of data and materials

NA

Abbreviations

ACE:

Angiotensin-Converting Enzyme

ADAM17:

A Disintegrin And Metalloprotease 17

Ang I:

Angiotensin I

Ang II:

Angiotensin II

ARB:

Angiotensin II type 1 receptor blocker

AT1R:

Angiotensin II type 1 receptor

COVID-19:

Corona Virus Disease 2019

NSAID:

Non-Steroid Anti-Inflammatory Drug

RAS:

Renin-Angiotensin-System

SARS:

Severe acute respiratory syndrome

SARS-CoV-2:

Severe acute respiratory syndrome coronavirus-2

TMPRSS2:

Serine protease transmembrane protease, serine 2

References

  1. 1.

    Panati K, Narala VR (2020) COVID-19 outbreak: an update on therapeutic options. SN Compr Clin Med In Press

  2. 2.

    Fang L, Karakiulakis G, Roth M (2020) Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 8:e21

    CAS  Article  Google Scholar 

  3. 3.

    Li W et al (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426(6965):450–454

    CAS  Article  Google Scholar 

  4. 4.

    Danser, AHJ, Epstein M, Batlle D (2020) Renin-Angiotensin System Blockers and the COVID-19 Pandemic: at present there is no evidence to abandon Renin-Angiotensin System Blockers. https://doi.org/10.1161/HYPERTENSIONAHA.120.15082.

  5. 5.

    Loder E, Rizzoli P (2018) Pharmacologic prevention of migraine: a narrative review of the state of the art in 2018. Headache 58(Suppl 3):218–229

    Article  Google Scholar 

  6. 6.

    Shamliyan TA et al (2013) Preventive pharmacologic treatments for episodic migraine in adults. J Gen Intern Med 28(9):1225–1237

    Article  Google Scholar 

  7. 7.

    Pomes LM et al (2019) Optimising migraine treatment: from drug-drug interactions to personalized medicine. J Headache Pain 20(1):56

    Article  Google Scholar 

  8. 8.

    Serfozo P et al (2020) Ang II (angiotensin II) conversion to angiotensin-(1-7) in the circulation is POP (Prolyloligopeptidase)-dependent and ACE2 (angiotensin-converting enzyme 2)-independent. Hypertension 75(1):173–182

    CAS  Article  Google Scholar 

  9. 9.

    Arendse LB et al (2019) Novel therapeutic approaches targeting the renin-angiotensin system and associated peptides in hypertension and heart failure. Pharmacol Rev 71(4):539–570

    Article  Google Scholar 

  10. 10.

    Ferrario CM et al (2005) Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111(20):2605–2610

    CAS  Article  Google Scholar 

  11. 11.

    Soler MJ et al (2009) Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan. Am J Physiol Ren Pysiol 296(2):F398–F405

  12. 12.

    Wang X et al (2016) The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang (1-7)-mas axes in pressure overload-induced cardiac remodeling in male mice. J Mol Cell Cardiol 97:180–190

    CAS  Article  Google Scholar 

  13. 13.

    Kurth T et al (2016) Migraine and risk of cardiovascular disease in women: prospective cohort study. BMJ 353:i2610

    Article  Google Scholar 

  14. 14.

    Qiao W et al (2015) Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic rats. Cardiology 131(2):97–106

    CAS  Article  Google Scholar 

Download references

Acknowledgements

The authors wish to thank Estrellita Uijl for her help in preparing the Figure.

Funding

Dr. Maassen van den Brink is funded by the Dutch Research Council (NWO, Vici grant 09150181910040).

Author information

Affiliations

  1. Dept. of Internal Medicine, Division of Pharmacology and Vascular Medicine, Erasmus MC University Medical Center Rotterdam, P.O. Box 2040, 3000, CA, Rotterdam, The Netherlands

    Antoinette MaassenVanDenBrink, Tessa de Vries & A. H. Jan Danser

Authors
  1. Antoinette MaassenVanDenBrink
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tessa de Vries
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. H. Jan Danser
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to this manuscript, which reflects our common opinion. The author(s) read and approved the final manuscript.

Corresponding author

Correspondence to Antoinette MaassenVanDenBrink.

Ethics declarations

Ethics approval and consent to participate

NA

Consent for publication

All authors have seen and approved the final version of this manuscript.

Competing interests

NA

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

MaassenVanDenBrink, A., de Vries, T. & Danser, A.H.J. Headache medication and the COVID-19 pandemic. J Headache Pain 21, 38 (2020). https://doi.org/10.1186/s10194-020-01106-5

Download citation

Keywords

  • COVID-19
  • Corona virus
  • Headache
  • Migraine
  • RAS inhibitors
  • Candesartan
  • Ibuprofen

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us